Alphatec's Q1 Miss Sparks a Mixed Response from Wall Street Alphatec Holdings' recent earnings report sent mixed signals to investors and analysts.
Some expressed concerns about the company's performance, while others see potential for growth in its surgical business.
The fiscal Q1 2026 results showed an 18% year over year decline in revenue from Alphatec's EOS business. Canaccord cut its price target to $23 from $25, despite maintaining a Buy rating on the shares.